SEC Form 4 · accession 0001209191-18-002065
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Raab
Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 5:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 2, 2018 | M | 9,366 | $15.00 | A | 15,180 | D | |
| Common StockF3 | Jan 2, 2018 | S | 9,366 | $15.00 | D | 5,814 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $2.81 | Jan 2, 2018 | M | 5,000 | D | Jun 15, 2011 | Jun 15, 2020 | Common Stock | 5,000 | 5,000 | D |
| Stock Options (right to buy) | $7.51 | Jan 2, 2018 | M | 4,366 | D | May 24, 2012 | May 24, 2021 | Common Stock | 4,366 | 5,634 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017.
- F2This price of $15.00 is the sole purchase price for the transactions reported on this line.
- F3This price of $15.00 is the sole sale price for the transactions reported on this line.